The guidelines are a first-of-its-kind effort to establish recommendations for the medical management of HS in seven ...

Serum level of inflammatory marker C-reactive protein (CRP) predicted response to adalimumab (Humira) treatment for patients ...

Adalimumab trough levels of 4.0 mg/L or higher among patients with RA were linked to greater treatment response and ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic ...

Adalimumab and secukinumab are the only FDA-approved biologic drugs to treat hidradenitis suppurativa, limiting options for ...

For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no ...

With high biologic treatment failure rates common among patients who have hidradenitis suppurativa (HS), investigators set ...

The company will protect the branded anti-interleukin (IL)-12/23 biologic against sales erosion from pending biosimilars.

Infliximab Remicaid® Chimeric monoclonal antibody iv. infusion, 3 mg/kg at 0, 2 and 6 weeks followed by maintenance every 4–8 weeks Golimumab Simponi® Human monoclonal antibody sc. injection ...

USA: A recent post hoc analysis of two randomized clinical trials has provided insight into the role of C-reactive protein ...

The sequence of biologic treatments in patients with inflammatory bowel disease significantly affects their risk of adverse ...